
Last updated: 2026-09-05 07:37:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Propanc Biopharma, Inc. (PPCB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.03, with a market capitalization of $2.35M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.95 to $65.00. This page covers its latest market performance, valuation, price trends and company information.
$2.35M | |
$1.05 | |
$67,500,000.00 | |
$0.95 | |
$1.02 | |
134.44K | |
-- | |
-- | |
$65.00 | |
$0.95 | |
-- | |
-- |
Propanc Biopharma, Inc. (PPCB) last closed at $1.02 as of 2026-09-04 23:55:00, unchanged from the previous close of $1.02.
During the latest regular trading session, PPCB traded between $0.95 and $67,500,000.00, with a volume of 134.44K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Propanc Biopharma, Inc. (PPCB) moved from $1.29 to $1.03, representing a decline of 20.54% ($0.27).
The stock traded between $0.99 and $1.06 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 14.84 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.1%
PPCB is currently trading at $1.03, placing it 0.1% of the way from its 52-week low of $0.95 to its 52-week high of $65.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Propanc Biopharma, Inc. (PPCB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.